Measurement of serum magnesium concentration in type 2 diabetic patients on glibenclamide and metformin therapy

Isam Hamo Mahmood*, Zaynab M. Ali Hassan**, Zeina Satam*
*Department of Pharmacology, ** Department of Biochemistry, College of Medicine, University of Mosul.

Received: 9th Jun 2010; Accepted: 25th Apr 2011.

ABSTRACT

Objectives: To measure serum magnesium concentrations in patients with type 2 diabetes on glibenclamide, metformin or a combination of both drugs therapy in Mosul city.

Patients and Methods: One hundred type 2 diabetic patients formed the patients group. Another group of 27 non diabetic healthy individuals involved in the study as a control group. The patients’ group was divided into 3 subgroups according to the type of the oral hypoglycemic agent used (metformin, glibenclamide, metformin plus glibenclamide). The study was conducted in Al Wafaa Diabetes Center in Mosul city, and departments of Pharmacology and Biochemistry, College of Medicine during the period from May 2009 to May 2010. Design of the study is case control. Quantitative analysis of magnesium and glucose in serum were done by using commercial kits.

Results: The results showed a significant lower concentration of magnesium of the patients as compared with the controls and a significant higher serum glucose concentrations of the patients as compared with the controls.

Conclusion: This study demonstrated that low magnesium status is common in type 2 diabetics who were on therapy with the hypoglycemic agents, metformin, glibenclamide or a combination of both drugs, in Mosul city.

Keywords: Magnesium, type 2 diabetes mellitus, glibenclamide, metformin.
Magnesium deficiency has been reported in type 2 diabetes mellitus. In the United States, 25–39% of diabetic outpatients have low concentrations of serum magnesium (1). Low serum magnesium concentrations in patients with type 2 diabetes have also been reported in several European countries, e.g., Austria, Germany, Italy, France, and Sweden (2–5).

Magnesium is the fourth most abundant cation in the human body and the second most abundant intracellular cation. It may exist as a protein bound, complexed, or free cation. It serves as a co-factor for all enzymatic reactions that require ATP and as a key component in various reactions that require kinases. It is also an essential enzyme activator for neuromuscular excitability and cell permeability, a regulator of ion channel and mitochondrial function, a critical element in cellular proliferation and apoptosis, and an important factor in both cellular and humoral immune reactions (6).

Magnesium depletion has a negative impact on glucose homeostasis and insulin sensitivity in patients with type 2 diabetes, as well as on the evolution of complications such as retinopathy, thrombosis and hypertension. Moreover, low serum magnesium is a strong independent predictor of the development of type 2 diabetes (7).

A large body of evidence that shows a link between hypomagnesemia and reduction of tyrosine kinase activity at the insulin receptor level, which may result in the impairment of insulin action and development of insulin resistance, has been progressively accumulated in previous years (8). Although evidence suggests that magnesium supplementation could be useful in the treatment of diabetes and to prevent the development of its chronic complications, the possible benefits of magnesium administration as an adjuvant factor for the treatment of type 2 diabetes, based in a randomized controlled trial, are scarce and controversial (8).

The aim of this study was to determine the serum magnesium concentrations of patients with type 2 diabetes on hypoglycemic therapy and healthy controls in Mosul city.

Patients and methods
One hundred type 2 diabetic patients and 27 non diabetic controls participated in the study. The patient’s group was divided into 3 groups according to the type of the oral hypoglycemic agent used (metformin, glibenclamide, metformin plus glibenclamide) (table 1). The diabetic patients were recruited from Al-Wafaa Center of Diabetes Mellitus in Mosul city. Twenty six of the patients were taking metformin, 32 were taking glibenclamide, and 42 were using both. The doses of the drugs ranged from 500 mg to 2000 mg daily in case of metformin and 5 to 10 mg in case of glibenclamide. Durations of treatment were 2.65±2.76 years in case of metformin, 4.01±4.52 years in case of glibenclamide and 3.62±3.13 years in case of met+glib therapy.

Because loop diuretics are associated with higher urinary magnesium excretion, patients on loop diuretics were excluded. None were taking magnesium supplements. The study protocol was approved by the Ethical Committee of the College of Medicine, University of Mosul.

Venous blood samples from the fasting control subjects and patients were drawn. Serum was separated from blood cells by centrifugation at 3000 rpm for 15 minutes and stored at -25°C until analysis.

Quantitative analysis of magnesium in serum was done by a photometric method (9) available as a commercial kit for measurement of magnesium (Biolabo, France). Serum glucose concentrations were estimated by glucose oxidase peroxidase colorimetric method (10) available as a kit provided by Randox Company, UK.
Table (1): Patient’s and control’s characteristics.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Metformin</th>
<th>Glibenclamide</th>
<th>Met+Glib</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>52.7±9.39</td>
<td>52.04±9.46</td>
<td>51.03±7.61</td>
<td>57.79±9.86</td>
</tr>
<tr>
<td>Male/ Female</td>
<td>12/15</td>
<td>17/9</td>
<td>15/17</td>
<td>22/20</td>
</tr>
<tr>
<td>Duration of treatment</td>
<td>------</td>
<td>2.65±2.76</td>
<td>4.01±4.52</td>
<td>3.62±3.13</td>
</tr>
<tr>
<td>No Patients</td>
<td>27</td>
<td>26</td>
<td>32</td>
<td>42</td>
</tr>
</tbody>
</table>

**Statistical analysis:** Unpaired t-test was used to compare serum magnesium or glucose concentrations of the controls and the patients. Linear regression analysis (Pearson Correlation Coefficient, r) was performed for finding the degree of association between serum glucose concentration and serum magnesium concentration. Level of significance at 0.05 or less.

**Results**

Mean serum magnesium concentrations of the diabetics and the controls appeared in (table 2). A significant lower level of magnesium as compared with those of the control individuals, were obtained from the patients (P=0.001 for metformin, 0.004 for glibenclamide, and 0.0001 for the drug’s combination).

Mean serum glucose concentrations of the diabetic group were significantly higher as compared with those of the control group, and were uncontrolled cases as evident by their high serum concentrations (table 3).

No correlation was found between serum glucose concentration and serum magnesium concentration of the different groups (r=-0.035 for glibenclamide, P= 0.84; r=0.26 for metformin, P=0.21; r= 0.07 for met+glib, P=0.66).

**Discussion**

The results in the present study showed that diabetic patients had low level of serum magnesium as compared with the control healthy subjects in Mosul city.

Similar findings have been obtained by other researchers in other countries. Pham et al. (6) stated that hypomagnesemia has been reported to occur at an increased frequency among patients with type 2 diabetes compared with their counterparts without diabetes in USA. Al-Osali et al. (11) showed that low total serum levels of magnesium are frequently seen in type 2 diabetic Omani patients. Seyoum et al. (12) reported that Ethiopians patients with diabetes mellitus have lower levels of magnesium and therefore at increased risk of complications related to magnesium. Low levels of magnesium in type 2 diabetic patients have also been reported in other countries including Italy (13), India (14), and Bangladesh (15).

The reasons for the high prevalence of magnesium deficiency in diabetes are not clear, but may include increased urinary loss, lower dietary intake, or impaired absorption of magnesium compared to healthy individuals (7). Several studies showed that intake of magnesium can correct the magnesium status.
of the diabetic patients. Rodriguez-Moran and Guerrero(8) reported that oral supplementation with magnesium chloride solution restores serum magnesium levels, improving insulin sensitivity and metabolic control in type 2 diabetic patients with decrease magnesium levels. De Lordes Lima(16) showed that magnesium depletion is common in poorly controlled patients with type 2 diabetes, especially in those with neuropathy or coronary disease. More prolonged use of magnesium in doses that are higher than usual is needed to establish its routine or selective administration in patients with type 2 diabetes to improve control or prevent chronic complications.

In the present study no correlation was found between serum glucose concentrations and serum magnesium levels. Several authors have described a correlation between HbA1c and plasma magnesium magnes in type 1 diabetics(4,17). However, no such a correlation was found in type 2 diabetes(4, 18, 19), similar to our results.

Clinically, there are significant data linking hypomagnesemia to various diabetic micro and macrovascular complications. In a study that involved 19 normotensive individuals without diabetes, 17 hypertensive individuals without diabetes, and 6 hypertensive individuals with diabetes, Resnick et al. (20) documented the lowest mean intracellular magnesium concentration among the last group. Two studies showed that not only did patients with diabetes have lower serum magnesium levels compared with their counterparts without diabetes, but also the serum magnesium levels among the cohort with diabetes had an inverse correlation with the degree of retinopathy(21, 22). In a comparative study that involved 30 patients who had type 2 diabetes without microalbuminuria, 30 with microalbuminuria, and 30 with overt proteinuria, Corsonello et al. (23) observed a significant decrease in serum ionized magnesium in both the microalbuminuria and overt proteinuria groups compared with the nonmicroalbuminic group. There also are data to suggest the association between hypomagnesemia and other diabetic complications, including dyslipidemia and neurologic abnormalities(24).

Serum glucose concentrations, in the present study, were high (the patient’s diabetic state is uncontrolled, in spite of using of hypoglycemic agents). Several studies have shown elevated urinary magnesium excretion in both type 1 and 2 diabetic patients, and elevated urinary magnesium excretion in diabetes is associated with elevated fasting blood glucose and Hb A1c concentrations(7). The lower magnesium concentrations in the present study may be due to the elevated levels of glucose concentrations reported in the present study. Pham et al. (25) reported that patients who have serum magnesium levels between 2.0 and 2.5 mg/ dl had the least degree of renal function deterioration and best glycemic control.

In conclusion, we have demonstrated that low magnesium status is common in type 2 diabetics who were on therapy with the hypoglycemic agents, metformin or glibenclamide or a combination of both drugs, in Mosul city in Iraq.

References


